Clinical trials: Episodic Migraine
Episodic Migraine
DFN-11 Injection in Episodic Migraine With or Without Aura
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
- Trial name
- RESTOR (NCT02569853)
- Testing
- DFN-11
- Where
- 16 sites in United States
- Volunteers
- 268 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Migraine Disorders
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Chronic Migraine (CM), or 15 or more migraine headaches per month, is common in tertiary headache care and is associated with a number of deleterious outcomes, especially higher disability and poorer quality of life, relative to…
- Trial name
- NCT01435941
- Testing
- Non-steroidal anti-inflammatory drug (NSAID), Triptan
- Volunteers
- 11,249 people
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Migraine Headache, Episodic
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
This is a randomized, blinded study designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of episodic migraine headaches.
- Trial name
- NCT01899040
- Testing
- neuromodulation for episodic migraine headache
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Scion NeuroStim
High Frequency Episodic Migraine and Chronic Migraine
TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine
This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
- Trial name
- NCT01839149
- Testing
- TI-001
- Where
- 6 sites in Australia, Chile and 1 more
- Volunteers
- 240 people
- Sponsor
- Trigemina, Inc
Episodic Migraine
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
- Trial name
- PROSPECT-1 (NCT05897320)
- Testing
- Eptinezumab
- Where
- 60 sites in United States, Argentina and 9 more
- Volunteers
- 315 people
- Sponsor
- H. Lundbeck A/S
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Migraine Disorders
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.
- Trial name
- NCT02183220
- Testing
- Metamizol, Acetylsalicylic acid (ASA)
- Volunteers
- 417 people
- Sponsor
- Boehringer Ingelheim
Episodic Migraine, Chronic Migraine
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
- Trial name
- MERANTI (NCT06625060)
- Testing
- Corabotase, Corabotase dose A, Corabotase dose B
- Where
- 162 sites in United States, Australia and 12 more
- Volunteers
- 670 people
- Sponsor
- Ipsen
Migraine
Safety, Efficacy and Pharmacokinetics of ALD403
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
- Trial name
- NCT01772524
- Testing
- ALD403
- Where
- 26 sites in United States
- Volunteers
- 163 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Migraine Disorders
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients
- Trial name
- RESET BRAIN (NCT03977649)
- Testing
- erenumab
- Where
- 5 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Episodic Migraine
Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain
Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.
- Trial name
- NCT04166045
- Testing
- Verum Treatment Location
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Theranova, L.L.C.
Migraine Disorders, Headache Disorders
Predicting Migraine Attacks Based on Environmental and Behavioral Changes as Detected From the Smartphone
This study is conducted at the Henry Ford Health System with Lifegraph's behavioral monitoring technology, to examine the relation between migraine attacks and behavioral and environmental changes as detected from the smartphone…
- Conditions
- Migraine Disorders, Headache Disorders, Headache Disorders, Primary, Brain Diseases
- Trial name
- Migraine (NCT03762902)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Lifegraph Ltd.
Migraine
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
- Trial name
- REJOIN (NCT05164172)
- Testing
- Eptinezumab
- Where
- 64 sites in United States, Argentina and 9 more
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Episodic Migraine
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
- Trial name
- NCT03939312
- Testing
- Atogepant
- Where
- 113 sites in United States
- Volunteers
- 685 people
- Sponsor
- Allergan